Advertisement
ARMP vs RANI
Which Stock Would AI Choose? Armata Pharmaceuticals (ARMP) vs. Rani Therapeutics (RANI) Stock Comparison
Key Takeaways
- ARMP is a late clinical-stage biotech advancing bacteriophage (virus-based) therapeutics against antibiotic-resistant infections, with its lead candidate AP-SA02 now moving toward a Phase 3 study in complicated Staphylococcus aureus bacteremia.
- RANI is a clinical-stage biotherapeutics company commercializing its RaniPill oral-delivery platform, with its RT-114 obesity candidate generating encouraging early bioavailability data.
- Both are pre-revenue or near-pre-revenue biotechs, but they face very different risk profiles: ARMP benefits from non-dilutive government funding, while RANI is contending with a Nasdaq minimum-bid-price compliance notice.
- Analyst consensus is bullish on both names, yet recent stock performance has diverged meaningfully, underscoring the value of a side-by-side relative performance review.
- You can track more details on these tickers' major news and today's price moves by visiting ARMP Major News and ARMP Today's Price Move, as well as RANI Major News and RANI Today's Price Move.
- To see how automated systems are currently positioning across the market, explore the curated Trending AI Robots section.
Introduction
Investors evaluating small-cap biotechnology frequently weigh innovation potential against funding and liquidity constraints. ARMP (Armata Pharmaceuticals) and RANI (Rani Therapeutics) both sit at the clinical-stage frontier, yet they pursue fundamentally different missions: one targets hard-to-treat bacterial infections, the other aims to replace injectable biologics with oral pills. This stock comparison is most relevant to growth-oriented and event-driven traders who follow clinical catalysts, regulatory milestones, and balance-sheet resilience. By examining business models, recent momentum, and market positioning, readers can better understand how these two names stack up in the current environment.
ARMP Overview and Recent Performance
Armata Pharmaceuticals is a late clinical-stage biotechnology company developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. Its lead candidate, AP-SA02, is a fixed multi-phage cocktail targeting complicated Staphylococcus aureus bacteremia (a serious bloodstream infection), including methicillin-resistant S. aureus (MRSA). Recent weeks have brought a series of clinical and regulatory advances: the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to AP-SA02, and the company announced additional non-dilutive funding from the U.S. Department of War, bringing total support for the program to roughly $32 million. Management has signaled plans to initiate a Phase 3 superiority study in the second half of 2026. Despite this pipeline progress, ARMP's share price has pulled back in recent market activity, with the stock trading well below its 52-week high. Analyst sentiment remains constructive, with published price targets well above current levels.
RANI Overview and Recent Performance
Rani Therapeutics Holdings is a clinical-stage biotherapeutics company focused on enabling oral administration of biologic drugs through its proprietary RaniPill capsule technology, which is designed to replace subcutaneous or intravenous injection. Its most closely watched program, RT-114, delivers PG-102, a GLP-1/GLP-2 dual agonist (a hormone-based treatment being studied for obesity), in partnership with ProGen. Recent data showed oral bioavailability above 150% relative to matched subcutaneous dosing, and the company has begun dosing a Phase 1a expansion cohort with additional data expected by year-end. Financially, RANI narrowed its quarterly net loss and recorded contract revenue tied to its Chugai collaboration. However, the stock has traded near the lower end of its 52-week range, and the company received a Nasdaq notice regarding its minimum bid price, adding a compliance-related overhang to sentiment.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of the platform's hundreds of AI trading bots, which together trade thousands of different tickers. Because bots vary widely in trading style, strategy, timeframe, performance statistics, and the sets of tickers they follow, only those best suited to current market conditions earn a place in this featured section. The curated list helps traders quickly identify automated strategies demonstrating consistent behavior in the present environment, rather than sifting through the full catalog manually. For investors comparing volatile small-cap biotech names like ARMP and RANI, reviewing these automated signals can add a quantitative layer to fundamental analysis. Explore the Trending AI Robots page to see which strategies are currently in focus.
Head-to-Head Comparison
The two companies diverge sharply across several dimensions. On business model, ARMP is a therapeutic developer advancing a specific anti-infective candidate, while RANI is a platform play whose value depends on broadly licensing or developing its delivery technology across multiple indications. Growth drivers also differ: ARMP's near-term catalysts are regulatory and clinical, anchored by Phase 3 initiation and government funding, whereas RANI's catalysts are data-driven, tied to RT-114 obesity results and partnership economics. On risk factors, ARMP benefits from non-dilutive funding and a parent relationship with Innoviva, but remains dependent on a single lead program; RANI faces a minimum-bid-price compliance deadline and ongoing capital needs, yet holds a diversified pipeline and collaboration revenue. Sector exposure is similarly distinct—anti-infectives versus metabolic and oral-biologics markets—making each stock sensitive to different investor sentiment cycles.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor ARMP at present. Its profile combines more clearly defined near-term catalysts (Breakthrough Therapy designation, Phase 3 readiness, and recurring non-dilutive funding) with a higher share price that provides greater distance from listing-compliance concerns. RANI's RT-114 data is promising, but the stock's depressed price, compliance overhang, and heavier reliance on future financing introduce comparatively more trend instability. This assessment is probabilistic rather than definitive: either name could re-rate quickly on clinical or regulatory news, and relative positioning can shift with a single announcement. Investors should treat the AI signal as one input within a broader analytical framework.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARMP is a Buy and RANI is a StrongBuy.
ARMP's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ARMP turned positive on October 20, 2026. Looking at past instances where ARMP's MACD turned positive, the stock continued to rise in 42 of 47 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ARMP's RSI Indicator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on ARMP as a result. In 90 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +26.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARMP advanced for three days, in 218 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
ARMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
ARMP moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ARMP entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.565) is normal, around the industry mean (3.498). P/E Ratio (-0.664) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.260) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ARMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
RANI's RSI Indicator climbs out of oversold territory
The RSI Oscillator for RANI moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 34 of the 39 cases the stock moved higher. This puts the odds of a move higher at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 65 of 76 cases where RANI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for RANI just turned positive on November 09, 2026. Looking at past instances where RANI's MACD turned positive, the stock continued to rise in 35 of 46 cases over the following month. The odds of a continued upward trend are 76%.
Following a +11.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where RANI advanced for three days, in 198 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RANI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RANI as a result. In 96 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RANI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RANI entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.609) is normal, around the industry mean (3.498). P/E Ratio (-4.206) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (21.459) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. RANI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RANI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ARMP | ||
|---|---|---|
OUTLOOK RATING 1..100 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 58 Fair valued | |
PROFIT vs RISK RATING 1..100 | 97 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 64 | |
P/E GROWTH RATING 1..100 | 14 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ARMP | RANI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 83% | 1 day ago 87% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| Momentum ODDS (%) | 1 day ago 85% | 3 days ago 90% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 76% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| Advances ODDS (%) | 5 days ago 86% | 5 days ago 80% |
| Declines ODDS (%) | 16 days ago 87% | 12 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 89% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARMP’s FA Score shows that 1 FA rating(s) are green while RANI’s FA Score has 2 green FA rating(s).
- ARMP’s FA Score: 1 green, 4 red.
- RANI’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARMP’s TA Score shows that 5 TA indicator(s) are bullish while RANI’s TA Score has 5 bullish TA indicator(s).
- ARMP’s TA Score: 5 bullish, 4 bearish.
- RANI’s TA Score: 5 bullish, 3 bearish.
Price Growth
ARMP (@Biotechnology) experienced а +24.00% price change this week, while RANI (@Biotechnology) price change was +1.74% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.04%. For the same industry, the average monthly price growth was -6.16%, and the average quarterly price growth was -16.99%.
Reported Earning Dates
ARMP is expected to report earnings on Mar 18, 2027.
RANI is expected to report earnings on Mar 31, 2027.
Industries' Descriptions
@Biotechnology (+2.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ARMP and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARMP has been loosely correlated with RANI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ARMP jumps, then RANI could also see price increases.
| Ticker / NAME | Correlation To ARMP | 1D Price Change % | ||
|---|---|---|---|---|
| ARMP | 100% | -4.37% | ||
| RANI - ARMP | 44% Loosely correlated | -7.54% | ||
| DMRA - ARMP | 34% Loosely correlated | -5.16% | ||
| SION - ARMP | 32% Poorly correlated | -7.30% | ||
| JANX - ARMP | 31% Poorly correlated | -7.22% | ||
| ARTV - ARMP | 30% Poorly correlated | -2.70% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IBTI | 22.07 | N/A | N/A |
| iShares iBonds Dec 2028 Term Treasury ETF | |||
| SDHY | 15.17 | -0.11 | -0.73% |
| PGIM Short Duration High Yield Opportunities Fund | |||
| PLTA | 17.02 | -0.13 | -0.76% |
| ProShares Ultra PLTR (PLTA) | |||
| CHPS | 72.88 | -0.89 | -1.21% |
| Xtrackers Semiconductor Select Equity ETF (CHPS) | |||
| TILL | 18.47 | -0.35 | -1.86% |
| Teucrium Agricultural Strategy No K-1 ETF (TILL) | |||